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Background. Expert-based genotypic interpretation systems are standard methods for guiding treatment selec-
tion for patients infectedwith human immunodeficiency virus type 1.We previously introduced the software pipeline
geno2pheno-THEO (g2p-THEO), which on the basis of viral sequence predicts the response to treatment with a
combination of antiretroviral compounds by applying methods from statistical learning and the estimated potential
of the virus to escape from drug pressure.
Methods. We retrospectively validated the statistical model used by g2p-THEO in 7600 independent
treatment-sequence pairs extracted from the EuResist integrated database, ranging from 1990 to 2007. Results were
compared with the 3 most widely used expert-based interpretation systems: Stanford HIVdb, ANRS, and Rega.
Results. The difference in receiver operating characteristic curves between g2p-THEO and expert-based ap-
proaches was significant (P  .001; paired Wilcoxon test). Indeed, at 80% specificity, g2p-THEO found 16.2%–
19.8%more successful regimens than did the expert-based approaches. The increased performance of g2p-THEOwas
confirmed in a 2001–2007 data set from which most obsolete therapies had been removed.
Conclusion. Finding drug combinations that increase the chances of therapeutic success is the main reason for
using decision support systems. The present analysis of a large data set derived fromclinical practice demonstrates that
g2p-THEO solves this task significantly better than state-of-the-art expert-based systems. The tool is available at
http://www.geno2pheno.org.
Several drug classes have been developed that target
HIV-1 replication at different stages. Although the re-
cently licensed coreceptor antagonists and integrase
inhibitors have just entered clinical practice, combina-
tions of nucleoside/nucleotide reverse-transcriptase in-
hibitors, nonnucleoside reverse-transcriptase inhibitors
(NNRTIs), and protease inhibitors (PIs) have been ex-
tensively used and still remain the backbone of most
highly active antiretroviral therapy (HAART) regimens.
Because of the high propensity of HIV-1 to develop re-
sistance to any antiretroviral compound, building an ef-
fective treatment regimen in clinical practice typically in-
volves screening the viral genome for known resistance
mutations. Several genotype interpretation systems infer in
vitro drug susceptibility and/or in vivo response to antiret-
roviral treatment on the basis of HIV-1 genotype. Most of
these tools use a set of rules carefully crafted by experts and
classify the virus as susceptible, intermediate, or resistant to
each of the single compounds. Few tools are fully data
driven rather than based on expert knowledge. For exam-
ple, geno2pheno[resistance] [1] and VirtualPhenotype [2]
applymethods from statistical learning to predicting in vi-
tro resistance on the basis of genotype.
Although all of these methods are designed to infer sus-
ceptibility to individual compounds [3], recently devel-
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oped decision support tools are being explored to infer virological
response directly to a typical 3–4-drug HAART regimen. In one
study [4], artificial neural networkswere used to predict the change
in viral load, given the sequence, regimen, and additional host-
specific features. In another recent work, we introduced the soft-
warepipelinegeno2pheno-THEO(g2p-THEO)[5],whichpredicts
the probability of reaching an undetectable viral load during the
course of the regimen given the applied drug combination and the
genetic makeup of the viral population. A quantitative and proba-
bilistic description of the genetic barrier to drug resistance was in-
cluded as an additional predictor. The genetic barrier is the esti-
mated probability that the virus will not escape from drug pressure
by developing additional mutations [6].
In this work, we present the external validation of g2p-THEO
in a data set containing 7600 treatment-sequence pairs collected
in a Europe-wide effort [7]. Virological response was dichoto-
mized, and performance was compared with 3 state-of-the-art
expert-based interpretation tools. In subsequent analyses, vari-
ous techniques of statistical learning were applied to (1) assess
the putative improvement in prediction accuracy incurred by
applying models for specific drug combinations and (2) investi-
gate the reliability of g2p-THEO when applied to unseen com-
binations of compounds—that is, those combinations that are
not contained in the training data set.
METHODS
Treatment change episodes (TCEs). The present study used
the previously introduced definition of a TCE [5], onwhich g2p-
THEO is based. Briefly, a TCE consists of a genotype, a drug
combination, and a binary outcome indicating success or fail-
ure. A genotype derived during ongoing therapy is considered a
failure, because a genotype can only be determined if the viral
load is sufficiently high (HIV RNA level of1000 copies/mL). A
success is observed if the new therapy that follows a genotypic
test can reduce the viral load to below the limit of detection once
during the course of the therapy. Although current assays have a
threshold of sensitivity of 40 or 50 copies, the 400-copy thresh-
old was used to include data obtained by earlier assays.
Data sets. The statistical model applied by g2p-THEO was
trained on data obtained from the Stanford HIV Drug Resis-
tance Database [8] (comprising data from clinical studies ACTG
320, ACTG 364, GART, and HAVANA) and from 2 northern
California clinic populations undergoing genotypic resistance
testing at Stanford University. From a total of 25,717 therapies,
10,288 sequences, and 6706 patients, 6359 TCEs were extracted
(4776 failing and 1583 successful therapies). This data set is here-
after called “Stanford-California.”Overrepresentation of certain
compounds in failing or successful therapies within the
Stanford-California data set led the statistical learningmodels to
often base their decisions only on the drug combination, irre-
spective of the genotype. To eliminate this artifact, g2p-THEO
was trained not on the full data set but on a subset that contained
the same number of failure- and success-associated genotypes
for every drug combination (see Altmann et al. [5] for details).
The number of genotypes per drug combination ranges from 2
to 446 (2478 TCEs in total). Hereafter, this data set is called
“Stanford-CaliforniaBT” (for “balanced therapies”). In some
analyses, both the Stanford-California and the Stanford-
CaliforniaBT data sets were evaluated again after removal of
zidovudine (ZDV)  lamivudine (3TC)  indinavir (IDV)
combination therapy, which was overrepresented because of the
inclusion of the large ACTG 320 data set. For further analysis, a
subset of Stanford-California containing only drug combina-
tions with 20 successes and 20 failures was selected. Only 6
treatmentsmet this requirement (table 1); hereafter, this data set
is called “Stanford-California6.”
Using the same definition, an independent TCE data set (Eu-
ResistDB) was extracted from the EuResist integrated database
(version 29.05.2007), comprising data from Germany (Arevir)
[9], Italy (ARCA) [10], and Sweden (Karolinska Institute). From
a total of 58,195 therapies, 19,258 sequences, and 16,999 pa-
Table 1. Distribution of failing and successful treatment change episodes for
the 6 most common regimens in the Stanford-California and EuResistDB data sets
(Stanford-California6 and EuResistDB6 subsets).
Stanford-California6 EuResistDB6
Regimen Failure Success Total Failure Success Total
ZDV3TCIDV 223 229 452 108 5 113
d4T3TCSQV/r 71 28 99 27 2 29
ddId4TEFV 96 54 150 132 25 157
d4T3TCEFV 60 27 87 114 16 130
ddId4TNFV 110 28 138 131 22 153
d4T3TCNFV 275 28 303 209 16 225
All regimens 835 394 1229 721 86 807
NOTE. 3TC, lamivudine; d4T, stavudine; ddI, didanosine; EFV, efavirenz; IDV, indinavir; NFV,
nelfinavir; SQV/r, saquinavir/ritonavir; ZDV, zidovudine.
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tients, we obtained 7603 TCEs (6217 failing and 1386 successful
therapies). For further analysis, we generated the subset EuRe-
sistDB6, comprising the same 6 drug combinations as in
Stanford-California6 (table 1). Because the EuResist integrated
database includes antiretroviral treatments started from 1990 to
2007, the main analysis was repeated on the TCE subset derived
from treatments started after 31 December 2000, to minimize
the contribution of obsolete therapy records.
Interpretation systems. ANRS (version 2006/07) [11], Rega
(version 7.1.1) [12], and Stanford HIVdb (version 4.3.0) [8] are
expert-based interpretation methods. These algorithms apply
carefully handcrafted interpretation rules or tables derived by
expert panels from the analysis of available in vitro and in vivo
resistance data. In addition, some rules of the ANRS algorithm
were derived from the statistical association between baseline
genotypic data and virological response. The classification gen-
erated by the interpretation systems was normalized into a score
by mapping susceptible (ANRS, Rega, and Stanford HIVdb) or
potential low-level resistance (Stanford HIVdb) to 1.0; interme-
diate (Rega) or possible resistance (ANRS) or low-level or inter-
mediate resistance (Stanford HIVdb) to 0.5; and resistant
(ANRS and Rega) or high-level resistance (Stanford HIVdb) to
0.0. Thus, the rating numerically represents the activity of a drug
against the virus on a scale ranging from 0 (inactive) to 1 (fully
active). Individual scores for NNRTIs and for boosted PIs com-
puted using the Rega algorithm were converted to 1.0, 0.25, and
0.0 and to 1.5, 0.75, and 0.0, respectively, as indicated by the
algorithm developers. The treatment score or genotypic suscep-
tibility score (GSS) [13] was then defined as the sum of single-
drug scores for the compounds included in the regimen.
g2p-THEO is a data-driven interpretation system that directly
computes a rating for a combination therapy. This value can be
interpreted as the probability of the viral load being reduced to be-
low the limit of detection during the course of therapy. g2p-THEO
represents the HIV-1 genotype by 49 indicator variables, each of
them indicating the presence (1) or absence (0) of a resistancemu-
tation [14] (for the complete list, see appendix A). Similarly, treat-
ment is encoded using 17 indicator variables, each representing the
presence (1) or absence (0) of a compound in the regimen (for the
list of considered compounds, see appendix A). In addition, viral
evolution during the course of therapy is represented by the genetic
barrier to drug resistance [6] for all drugs in the regimen. The ge-
netic barrier is the probability that the virus will remain susceptible
under drug pressure, given as a numerical value between 0 (no ge-
netic barrier [i.e., the virus is expected to become resistant]) and 1
(insurmountable genetic barrier [i.e., the virus is expected to re-
main susceptible]). Together with the indicator variables, the ge-
netic barrier (1 value per drug) is used as input to the logisticmodel
tree (LMT) [15] applied by g2p-THEO to compute a score for a
combination therapy.
Receiver operating characteristic (ROC) curves. ROC curves
depict classifier performance by giving a true-positive rate (TPR;
percentage of correctly predicted successes) for every false-positive
rate (FPR; percentage of failing therapies [i.e., with a genotype ob-
tained during treatment] that were predicted to be successful [i.e.,
to decrease viral load to 400 copies/mL]). The area under the
ROC curve (AUC) summarizes the performance and is a conve-
nient measure for comparing scoring systems without the need to
provide a particular cutoff [16]. Briefly, the AUC is a value between
0 and 1 corresponding to the probability that a randomly selected
success receives ahigher score thana randomly selected failure [17].
ROCR software (version 1.0-2) [18]was used for theROCanalysis.
Comparative analysis. The statistical model applied by g2p-
THEO was used to predict the outcome of the genotype-therapy
pairs in the external EuResistDB data set. The performance was
compared with that of the 3 expert-based interpretation tools:
ANRS, Rega, and Stanford HIVdb. The EuResistDB data set was
usedasan independent test set.Onehundredbootstrapreplicatesof
the EuResistDB data set were used for computing SDs.
Stability. To further analyze the robustness of the approach,
the prediction of response to drug combinations that were not
present in the training data was simulated by a variant of cross-
validation on the training data. In standard cross-validation, the
available data are split randomly into n equally sized nonoverlap-
ping subsets. Then, n 1 pooled subsets are used as a training set,
and the remaining subset is used as a test set to compute the perfor-
mance of the model. This procedure is repeated n times. Hence,
every subset is used as a test set once. To simulate the prediction of
unseen drug combinations, the splits were not carried out
randomly, and every subset contained only TCEs with the same
drug combination. Results derived by this “therapy-fold” cross-
validationwere comparedwith results of standard cross-validation,
with the number of folds equal to the number of different drug
combinations.Asubstantial loss inperformance (e.g., a lossof0.1 in
AUC) for the therapy-fold cross-validation comparedwith thenor-
mal protocol indicates unstable behavior with respect to unseen
drug combinations, because it indicates the requirement to include
examples of the drug combination that should be predicted in the
trainingdata formaintaining theperformance.Theexperimentwas
repeated on the special subset Stanford-CaliforniaBT and on the
complete EuResistDB data set. Because of limited computational
resources, the LMT applied by g2p-THEO was replaced by the
faster linear support vector machines (SVMs) [19], with similar
predictive performance.
Regimen-specific models. For some drug combinations,
many samples were available. Models trained exclusively on
TCEs for 1 drug combination are expected to predict response to
that regimen more accurately than models trained on all avail-
able TCEs. The Stanford-California6 subset contained sufficient
data for training 6 regimen-specific models and for measuring
their performance. The performance of the individual models
was assessed by 10 repetitions of 5-fold cross-validation on data
comprising only 1 drug combination. The performance of the
full model was assessed by 10 repetitions of a variant of 5-fold
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cross-validation in which all TCEs with other drug combina-
tions were added to the 4 subsets forming the training data.
SVMs with a linear kernel were used as a statistical learning
method. Performance in an independent test set was assessed by
predicting the outcome of TCEs in EuResistDB6 with the full
model and the 6 regimen-specific models (10 repetitions). Re-
sults were compared with those obtained using g2p-THEO and
the 3 expert-based interpretation tools.
RESULTS
Comparative analysis. Figure 1 depicts the ROC curves for
the 3 expert-based interpretation tools and g2p-THEO. The
curves for Stanford HIVdb, ANRS, and Rega did not differ sub-
stantially, resulting in comparable TPRs and FPRs for every GSS
cutoff. In contrast, in the FPR range from 0% to 40%, the curve
for g2p-THEO was distinctly located above all the other curves.
For higher FPRs, all curves proceeded with similar slopes. The
AUC value for g2p-THEOwas significantly larger than those for
the expert-based approaches (P  .001; paired Wilcoxon test).
ROC curves allow for a detailed analysis of specific points on the
curve. For example, at a FPR of 20% (close to a GSS cutoff of 2.5
for Rega and ANRS and of 2.0 for Stanford HIVdb), Stanford
HIVdb, ANRS, and Rega yielded TPRs of 44.2% (SD, 3.2%),
47.8% (SD, 2.7%), and 46.5% (SD, 2.2%), respectively. In con-
trast, at the same FPR g2p-THEO achieved a TPR of 64.0% (SD,
1.6%). On the other hand, at a false-negative rate (FNR) of 10%
(close to a GSS cutoff of 1.0 for all systems), Stanford HIVdb,
ANRS, and Rega yielded true-negative rates of 54.1% (SD,
2.0%), 51.0% (SD, 2.1%), and 55.9% (SD, 0.8%), respectively,
compared with 54.7% (SD, 1.8%) for g2p-THEO. Restriction of
the EuResistDB data set to therapies started after 31 December
2000 led to an even more pronounced difference in AUC be-
tween g2p-THEO (0.824 [SD, 0.006]) and the expert-based ap-
proaches (for Stanford HIVdb, 0.728 [SD, 0.008]; for ANRS,
0.733 [SD, 0.008]; for Rega, 0.754 [SD, 0.007]).
Stability. Table 2 summarizes the results of the stability anal-
ysis. The standard cross-validation performance on the Stanford-
California data set was in line with previously published results [5].
For both Stanford-California data sets containing the highly prev-
alent ZDV3TCIDV regimen, the therapy-fold cross-validation
yielded slightlyworse results than the standard protocol (difference
inAUCof0.03). In contrast, in the EuResistDBdata set and both
Stanford-California data sets without ZDV3TCIDV, no loss in
performance was observed.
Regimen-specific models. Table 3 shows the mean AUC
and SD for the regimen-specific models and the full model for
Figure 1. Receiver operating characteristic (ROC) curves for the EuResistDB data set. Every method is represented by a single ROC curve, namely Stanford
HIVdb, ANRS, Rega, and geno2pheno-THEO (g2p-THEO). Each point on the curve represents a classifier with a different cutoff and allows the true-positive rate
(TPR) and false-positive rate (FPR) for that cutoff to be determined. Whiskers indicate the SDs of the TPRs at a specific FPR. The genotypic susceptibility score
(GSS) and predicted success probability (p) cutoffs leading to specific TPR and FPR values are indicated within the plot for expert-based approaches and
g2p-THEO, respectively. For each method, the area under the ROC curve and its SD are given parenthetically in the box.
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the 6 most common drug combinations in the Stanford-
California data set. The results for the combination of stavudine
(d4T) 3TC saquinavir/ritonavir (SQV/r) were the worst for
both models, and there was no benefit in using the regimen-
specific model. However, for the remaining 5 drug combina-
tions, the benefits of regimen-specificmodels ranged from 0.017
to 0.048 and reached statistical significance. Within the EuRe-
sistDB6 data set, an insufficient number of successful TCEs was
available for ZDV3TCIDV and d4T3TCSQV/r (table 1).
The full model outperformed the regimen-specific model only
for d4T  3TC  efavirenz (EFV). For the remaining 3 drug
combinations, the benefit of the regimen-specific model was
more pronounced than in the cross-validation setting and
ranged from 0.046 to 0.301 for d4T 3TC nelfinavir (NFV),
a combination for which the full model actually failed to make
useful predictions. The LMTs in g2p-THEO also outperformed
the regimen-specificmodel for d4T3TCEFV. In the remain-
ing 3 cases, the benefit of the regimen-specific models ranged
from 0.011 to 0.082. All regimen-specific models outperformed
the expert-based methods.
Figure 2 depicts the ROC curves for the regimen-specificmodels
(g2p-THEO-SVM-RS), the full model (g2p-THEO-SVM), g2p-
THEO, and the expert-based methods applied to the EuResistDB6
data set. The full model performed better than the expert-based
methods in the areabelowaFPRof 32%butworse in the remaining
region. As in the previous ROC plot (figure 1), g2p-THEO per-
Table 2. Area under the receiver operating characteristic curve (AUC) values
obtained by standard cross-validation and therapy-fold cross-validation.
AUC
Data set
Drug combinations,
no.
Standard
cross-validation
Therapy-fold
cross-validation
Stanford-California
With ZDV3TCIDV 876 0.901 0.870
Without ZDV3TCIDV 875 0.898 0.895
Stanford-CaliforniaBT
With ZDV3TCIDV 323 0.838 0.812
Without ZDV3TCIDV 322 0.812 0.813
EuResistDB 712 0.847 0.844
NOTE. The rows of the table correspond to the 5 data sets, with both Stanford-California data
sets studied with and without the zidovudine (ZDV)  lamivudine (3TC)  indinavir (IDV) drug
combination, in light of the overrepresentation of this regimen caused by the ACTG 320 data.
(Stanford-CaliforniaBT is the “balanced therapies” subset; see Methods for a detailed explanation.)
Note that computation of the AUC requires positive and negative samples, but because of the
nature of therapy-fold cross-validation, it could not be ensured that positive and negative samples
were present in every subset of the cross-validation. Thus, it was not possible to compute foldwise
AUC values or their SDs and statistical significance.
Table 3. Area under the receiver operating characteristic curve (AUC) values for cross-validation and training test set-up.
Stanford-California6 EuResistDB6, AUC
Regimen
Regimen-specific
model, AUC
Full model,
AUC P
Regimen-specific
model Full model g2p-THEO
Stanford
HIVdb ANRS Rega
ZDV3TCIDV 0.965 (0.005) 0.928 (0.002) .001 0.596 (0.038) 0.570 0.610 0.656 0.692 0.755
D4T3TCSQV/r 0.747 (0.035) 0.740 (0.022) .256 0.420 (0.012) 0.815 0.444 0.407 0.463 0.426
ddId4TEFV 0.988 (0.006) 0.950 (0.002) .001 0.925 (0.003) 0.879 0.914 0.803 0.798 0.777
d4T3TCEFV 0.924 (0.028) 0.876 (0.015) .003 0.727 (0.016) 0.771 0.769 0.693 0.724 0.708
ddId4TNFV 0.974 (0.005) 0.957 (0.005) .001 0.821 (0.008) 0.709 0.739 0.665 0.671 0.684
d4T3TCNFV 0.946 (0.010) 0.915 (0.010) .001 0.829 (0.016) 0.528 0.782 0.782 0.781 0.784
Mean 0.924 0.895 . . . 0.720 0.712 0.710 0.668 0.688 0.689
Full data set . . . . . . . . . 0.810 (0.005) 0.733 0.781 0.707 0.718 0.707
NOTE. Rows correspond to the 6 regimens in the 2 data sets. The columns for the Stanford-California6 data show the AUC values derived by 10 repetitions
of 5-fold cross-validation for the regimen-specific models and the full model using all available training data (SDs are in parentheses); P values for the comparison
of the performances of the 2 models were obtained by the Wilcoxon rank-sum test. The columns for the EuResistDB6 data set show the AUC values for the
regimen-specific models (SDs are in parentheses), with the full model using all Stanford-California data, the original geno2pheno-THEO (g2p-THEO) predictions,
and the 3 expert-based approaches (Stanford HIVdb, ANRS, and Rega). 3TC, lamivudine; d4T, stavudine; ddI, didanosine; EFV, efavirenz; IDV, indinavir; NFV,
nelfinavir; SQV/r, saquinavir/ritonavir; ZDV, zidovudine.
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formed better than the expert-based interpretation tools in the area
below a 50% FPR and performed as well in the remaining region.
However, the regimen-specific models outperformed the other
methods over the whole range of FPRs. More specifically, they
yielded a TPR of 58.4% at a FPR of 20%, compared with 39.8% for
the expert-basedmethods and 53.6% for g2p-THEO.
DISCUSSION
Validation of HIV genotype interpretation systems is a crucial
step in translating computer-basedmethods into clinically effec-
tive treatment decision support tools. In the present study, using
an external data set of7600 TCEs extracted from the EuResist
integrated database, the recently developed g2p-THEO system
was shown to outperform the 3 most widely used expert-based
interpretation systems. Although the EuResist data set included
many obsolete therapies because of its long observation period,
the same results were confirmed when therapies started before 1
January 2001 were removed. The g2p-THEO system was more ac-
curate than ANRS, Stanford HIVdb, and Rega by 16.2%–19.8% in
the detection of therapeutic success (20% FPR). However, all of
the systems were comparable in detecting treatment failure at a
10% FNR. This finding suggests that expert-based systems are
better suited to detect the failure of therapy than to detect suc-
cess, probably because their original purpose was to detect resis-
tance to individual drugs. However, whether a treatment will
most likely be successful is exactly the response a user expects
from a decision support tool. Current expert-based approaches
are indeed evolving into clinically oriented tools aimed at build-
ing effective combination regimens. Computing a regimen GSS
by simple summation of the individual drug scores derived by
expert-based systems fails by definition to weight both different
drug potencies and drug interaction effects. However, such an
unweightedGSS is still commonly used [20, 21] in the absence of
any agreed-upon standard for a weighted GSS. Notably, the lat-
est Rega algorithm has introduced arbitrary drug weights in an
attempt to account for the expected increased potency of
ritonavir-boosted PIs and a lack of intermediateNNRTI activity.
The superior performance of g2p-THEO may have derived
from 2 factors. First, the calculated genetic barrier provides use-
ful information by estimating the probability of viral evolution
under drug pressure [5]. Second, the training process assigns
weights to all drugs. Hence, during the decisionmaking process,
drugs are not treated equally. As shown in Altmann et al. [22],
this can significantly improve the performance of genotype in-
terpretation tools. On the other hand, g2p-THEO is currently
limited to a set of well-established resistance mutations, which
might explain its inability to improve the detection of failing
regimens.
Figure 2. Receiver operating characteristic (ROC) curves for regimen-specific models applied to the EuResistDB6 data set. Every method is represented by
a ROC curve for a subset of the EuResistDB data comprising 6 different treatments. In addition to the methods depicted in figure 1, ROC curves are shown
for g2p-THEO-SVM (geno2pheno-THEO [g2p-THEO] in which logistic model trees were replaced by support vector machines [SVMs]) and g2p-THEO-SVM-RS
(g2p-THEO using regimen-specific SVMs). For each method, the area under the ROC curve is given parenthetically in the box.
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In the computation of a score for a drug combination, the ro-
bustness of the tool with respect to unseen drug combinations is an
important issue. In both Stanford-California data sets, a slight de-
crease in the AUC was observed in predictions for unseen drug
combinations. Overrepresentation of ZDV3TCIDV therapy
due to inclusion of the ACTG 320 clinical trial in the data sets was
identified as a possible confounder of this analysis, because no de-
crease in performance with unseen drug combinations was ob-
served after removal of TCEs containing the ZDV3TCIDV
combination. Thus, our stability analysis indicated that g2p-THEO
returns reliable scores for unobserved drug combinations. Thema-
jor reason for thepreservationof performance is that theprediction
is based on a linear model. Indeed, during the learning process of
the linearmodel, contributions of every single covariate to the out-
comeare computed.This alsoholds for drugs in a regimen, because
the impact has to be distributed among these drugs. In the end,
observedandunobserveddrugcombinationsarebothcomposedof
observed compounds. However, this property is also a potential
disadvantage of linearmodels. Specifically, if the prediction is based
on a linear model, the synergistic effects between drugs or muta-
tions cannot be represented unless a large number of covariates are
introduced to explicitlymodel these effects. In contrast, in regimen-
specific models all mutations are evaluated in the context of the
same drug combination, thus rendering the explicit modeling of
interactions unnecessary. In the Stanford-California6 data set, the
regimen-specific models for all drug combinations exhibited in-
creased performance compared with the full model, even though
the fullmodel hadaccess tomanymore training samples. This find-
ing was confirmed in independent data. However, the benefit of
regimen-specificmodels decreasedwhen they were comparedwith
the full statistical model for g2p-THEO. This can be explained by
the fact that g2p-THEO applies LMTs that directly train multiple
linear models on distinct subsets of the training data. Unfortu-
nately, only a few outdated regimens gave rise to enough training
data for regimen-specific models. However, a promising approach
has been recently proposed [23], one that pools data on “similar”
regimens to overcome this limitation in generating regimen-
specific models.
A major issue with any fully data-driven system is the in-
ability to generate predictions for newly licensed compounds
because of the delayed availability of sufficient training data.
This drawback can be addressed only by multicenter efforts
and cooperation between drug companies and regulatory
bodies for immediate release of clinical trial data. However,
because an optimized background regimen is recommended
for the effective use of any new compound, interpretation
systems are still relevant for choosing the backbone drugs,
particularly in heavily experienced patients. Expert-based
systems can complement data-driven systems for predicting
the activity of novel drugs until sufficiently large genotype-
response data sets are available.
Data-driven systems need a large amount of data for training, so
observational cohort data are often used. These provide a valuable
source for assessing the impact that drug resistance has on the re-
sponse to treatment but typically lack other relevant information,
including adherence levels and pharmacokinetics data. Weighting
for these factors is expected to help us develop better systems aimed
at building effective regimens. It must also be noted that modern
and future antiretroviral treatment strategies are expected to limit
the development of drug resistance by providing increased potency
and convenience, perhaps making treatment toxicity issues rela-
tivelymore relevant than resistance over time.However, drug resis-
tance and cross-resistance remain issues for a substantial propor-
tion of patients harboring viral populations that display a complex
mutational pattern because of multiple treatment failures. In addi-
tion, toxicity is also a major contributor to the selection of drug
resistance through decreased adherence. Developed as a clinically
oriented tool, g2p-THEO allows the user to exclude specific drugs
for toxicity issues and provides a total pill count for each regimen.
Although no data-driven system is meant to replace a comprehen-
sive patient evaluation by an expert HIV specialist, validated tools
such as g2p-THEO can provide an appropriate support to most
caregivers of HIV-infected patients.
APPENDIX A
INDICATOR VARIABLES AND SVM SETTINGS
We used indicators for the following mutations: for protease, 10F/
I/R/V, 16E, 20M/R/I, 24I, 30N, 32I, 33F/I/V, 36I/L/V, 46I/L, 47V/A,
48V, 50L/V, 53L, 54L/V/M/T/A/S, 60E, 62V, 63P, 71V/T/I/L, 73S/
A/C/T, 77I, 82A/F/T/S, 84V, 88D/S, 90M, and 93L; for reverse
transcriptase, 41L, 44D, 62V, 65R, 67N, 70R, 74V, 75T/M/S/A/I,
77L, 100I, 103N, 106A/M, 108I, 115F, 116Y, 118I, 151M, 181C/I,
184V/I, 188C/L/H, 190S/A, 210W, 215F/Y, and 219Q/E. We con-
sidered the following compounds: ZDV, zalcitabine, didanosine,
d4T, 3TC, abacavir, tenofovir, nevirapine, delavirdin, EFV, SQV,
IDV, ritonavir boosting dose, NFV, amprenavir, lopinavir, and
atazanavir. The settings used for the SVM are shown in table A1.
Table A1. Support vector machine settings.
Analysis, setting Kernal  C
Stability analysis
All Linear 0.1 1
Regimen-specific models
Regimen specific Linear 0.1 C optimizing AUC in
5-fold CV
All Linear 0.1 4 (optimized AUC in
10-fold CV)
NOTE. C, cost factor; CV, cross-validation; AUC, area under the re-
ceiver operating characteristic curve.
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